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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation-in-part of International 
Application No. PCT/US2005/005665, ?led Feb. 23, 2005, 
the content of Which is herein incorporated by reference in its 
entirety. 
FIELD OF THE INVENTION 
The invention relates to compositions and methods for 
reducing the level of nornicotine and its metabolite, N'-ni 
trosonornicotine, in a plant that is a member of the genus 
Nicoliana, particularly compositions and methods for inhib 
iting expression or function of a cytochrome P450 polypep 
tide involved in the metabolic conversion of nicotine to nor 
nicotine. 
BACKGROUND OF THE INVENTION 
The predominant alkaloid found in commercial tobacco 
varieties is nicotine, typically accounting for 90-95% of the 
total alkaloid pool. The remaining alkaloid fraction is com 
prised primarily of three additional pyridine alkaloids: nor 
nicotine, anabasine, and anatabine. Nornicotine is generated 
directly from nicotine through the activity of the enzyme 
nicotine N-demethylase (FIG. 1). Nornicotine usually repre 
sents less than 5% of the total pyridine alkaloid pool, but 
through a process termed “conversion,” tobacco plants that 
initially produce very loW amounts of nornicotine give rise to 
progeny that metabolically “convert” a large percentage of 
leaf nicotine to nornicotine. In tobacco plants that have 
genetically converted (termed “converters”), the great major 
ity of nornicotine production occurs during the senescence 
and curing of the mature leaf (Wernsman and Matzinger 
(1968) Tob. Sci. 121226-228). Burley tobaccos are particu 
larly prone to genetic conversion, With rates as high as 20% 
per generation observed in some cultivars. 
During the curing and processing of the tobacco leaf, a 
portion of the nornicotine is metabolized to the compound 
N'-nitrosonomicotine (NNN; FIG. 1), a tobacco-speci?c nit 
rosamine (TSNA) that has been shoWn to be carcinogenic in 
laboratory animals (Hecht and Hoffmann (1990) Cancer Sur 
veys 81273-294; Hoffmann et al. (1994) .1. Toxicol. Environ. 
Health 4111-52; Hecht (1998) Chem. Res. Toxicol. 111559 
603). In ?ue-cured tobaccos, TSNAs Were found to be pre 
dominantly formed through the reaction of alkaloids With the 
minute amounts of nitrogen oxides present in combustion 
gases formed by the direct-?red heating systems found in 
traditional curing barns (Peele and Gentry (1999) “Formation 
of Tobacco-speci?c Nitrosamines in Flue-cured Tobacco,” 
CORESTA Meeting, Agro-Phyto Groups, Suzhou, China). 
Retro?tting these curing barns With heat-exchangers virtually 
eliminated the mixing of combustion gases With the curing air 
and dramatically reduced the formation of TSNAs in tobac 
cos cured in this manner (Boyette and Ham (2001 ) Rec. Adv. 
Tob. Sci. 27117-22). In contrast, in the air-cured Burley tobac 
cos, TSNA formation proceeds primarily through reaction of 
tobacco alkaloids With nitrite, a process catalyzed by leaf 
bome microbes (Bush et al. (2001) Rec. Adv. Tob. Sci. 27123 
46). Thus far, attempts to reduce TNSAs through modi?ca 
tion of curing conditions While maintaining acceptable 
quality standards have not proven to be successful for the 
air-cured tobaccos. 
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In Burley tobaccos, a positive correlation has been found 
betWeen the nornicotine content of the leaf and the amount of 
NNN that accumulates in the cured product (Bush et al. 
(2001) Rec. Adv. Tob. Sci. 27123-46; Shi et al. (2000)Tob. 
Chem. Res. Conf 541Abstract 27). HoWever, keeping norni 
cotine levels at a minimum has been dif?cult because of the 
conversion phenomenon that results in a continual introduc 
tion of high nornicotine-producing plants Within commer 
cially groWn Burley populations. Minimizing the number of 
Burley plants that accumulate high levels of nornicotine has 
traditionally been the responsibility of plant breeders and 
seed producers. Though the percentage of converter plants 
that are ultimately groWn in farmers’ ?elds can be reduced 
through the roguing of converter plants during the propaga 
tion of seed stocks, this process is costly, time-consuming, 
and imperfect. 
Previous studies have shoWn that once a plant has con 
ver‘ted, the high nornicotine trait is inherited as a single domi 
nant gene (Grif?th et al. (1955) Science 1211343-344; Burk 
and Jeffrey (1958) Tob. Sci. 21139-141; Mann et al. (1964) 
Crop Sci. 41349-353). The nature of this gene, hoWever, is 
currently unknoWn. In the most simple of scenarios, the con 
version locus may represent a nonfunctional nicotine N-dem 
ethylase gene that regains its function in converter plants, 
possibly through the mobilization of a mutation-inducing 
transposable element. Alternatively, the converter locus may 
encode a protein that initiates a cascade of events that ulti 
mately enables the plant to metabolize nicotine to nomico 
tine, Which Would mean that multiple genes may be involved. 
Regardless of Whether there are one or many genes asso 
ciated With the conversion process, it is clear that the gene(s) 
encoding polypeptides having nicotine demethylase activity 
play a pivotal role in this process. Although the inability to 
purify active nicotine N-demethylase from crude extracts has 
impeded the isolation and identi?cation of this enzyme, there 
is some evidence that a member of the cytochrome P450 
superfamily of monooxygenases may be involved (Hao and 
Yeoman (1996) Phylochem. 411477-482; Hao and Yeoman 
(1996) Phylochem. 421325-329; Chelvarajan et al. (1993) J. 
Agric. Food Chem. 411858-862; Hao and Yeoman (1998) J 
Plant Physiol. 1521420-426). HoWever, these studies are not 
conclusive, as the classic P450 inhibitors carbon monoxide 
and tetcylasis have failed to loWer enzyme activity at rates 
comparable to other reported P450-mediated reactions (Chel 
varajan et al. (1993) .1. Agric. Food Chem. 411858-862). 
Furthermore, the cytochrome P450s are ubiquitous, trans 
membrane proteins that participate in the metabolism of a 
Wide range of compounds (revieWed by Schuler (1996) Cril. 
Rev Plant Sci. 151235-284; Schuler and Werck-Reichhart 
(2003)Annu. Rev. Plant Biol. 541629-667). Examples ofbio 
chemical reactions mediated by cytochrome P450s include 
hydroxylations, demethylations, and epoxidations. In plants, 
the cytochrome P450 gene families are very large. For 
example, total genome sequence examination has revealed 
272 predicted cytochrome P450 genes in Arabidopsis and at 
least 455 unique cytochrome P450 genes in rice (see, for 
example, Nelson et al. (2004) Plant Physiol. 135(2)1756 
772). Even though cytochrome P450 has been implicated as 
having a role in the metabolic conversion of nicotine to nor 
nicotine, identi?cation of key participating members of this 
protein family remains a challenge. 
Aside from serving as a precursor for NNN, recent studies 
suggest that the nornicotine found in tobacco products may 
have additional undesirable health consequences. Dickerson 
and Janda demonstrated that nornicotine causes aberrant pro 
tein glycation Within the cell (Dickerson and Janda (2002) 
Proc. Natl. Acad. Sci. USA 99115084-15088). Concentrations 
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of nornicotine-modi?ed proteins Were found to be much 
higher in the plasma of smokers compared to nonsmokers. 
Furthermore, this same study shoWed that nornicotine can 
covalently modify commonly prescribed steroid drugs such 
as prednisone. Such modi?cations have the potential of alter 
ing both the e?icacy and toxicity of these drugs. 
In vieW of the dif?culties associated With conversion and 
the undesirable health effects of nomicotine accumulation, 
improved methods for reducing the nomicotine content in 
tobacco varieties, particularly Burley tobacco, are therefore 
desirable. Such methods Would not only help ameliorate the 
potential negative health consequences of the nornicotine per 
se as described above, but should also concomitantly reduce 
NNN levels. 
SUMMARY OF THE INVENTION 
Compositions and methods for reducing the nornicotine 
content in plants that are members of the genus Nicoliana are 
provided. Compositions include isolated cytochrome P450 
polynucleotides and polypeptides that are involved in the 
metabolic conversion of nicotine to nornicotine in plants, 
particularly Nicoliana species. The isolated polynucleotides 
comprise the nucleotide sequence set forth in SEQ ID NO: 1, 
3, 5, 7, 9, or 1 l, a nucleotide sequence encoding a polypeptide 
as set forth in SEQ ID N012, 4, 6, 8, 10, or 12, and fragments 
and variants thereof. Isolated polypeptides of the invention 
comprise an amino acid sequence set forth in SEQ ID N012, 
4, 6, 8, 10, or 12, an amino acid sequence encoded by the 
nucleotide sequence set forth in SEQ ID NOzl, 3, 5, 7, 9, or 
11, and fragments and variants thereof. 
The polynucleotides of the invention ?nd use in suppress 
ing expression of a cytochrome P450 that is involved in the 
metabolic conversion of nicotine to nornicotine in a plant, 
including the cytochrome P450s of the present invention. In 
this manner, compositions further include expression cas 
settes comprising an inhibitory sequence that is capable of 
inhibiting expression or function of a cytochrome P450 
polypeptide of the invention, Where the inhibitory sequence is 
operably linked to a promoter that is functional in a plant cell. 
In some embodiments, the inhibitory sequence comprises the 
sequence set forth in SEQ ID NOzl, 3, 5, 7, 9, ll, l3, l4, 15, 
or 16, or a complement or fragment thereof. Compositions 
also include transformed plants and plant parts that comprise 
an expression cassette of the present invention, optionally 
stably incorporated into the genome of the plant. Further 
provided are tobacco products, including cheWing tobacco, 
snuff, cigarettes, pipe tobacco, and cigars, having a reduced 
level of nomicotine, and its related nitrosamine, N'-nitroso 
nomicotine. 
The methods of the invention comprise inhibiting the 
expression or function of a cytochrome P450 polypeptide of 
the present invention. In some embodiments, an expression 
cassette comprising an inhibitory sequence that targets 
expression or function of a cytochrome P450 polypeptide of 
the present invention is introduced into the plant or plant part 
of interest, Wherein expression of the inhibitory sequence 
produces a polynucleotide or polypeptide that inhibits 
expression or function of a cytochrome P450 polypeptide of 
the invention. In one such embodiment, the inhibitory 
sequence comprises a sequence set forth in SEQ ID NO: 1, 3, 
5, 7, 9, ll, l3, l4, 15, or 16, or a complement or fragment 
thereof. 
The methods of the invention ?nd use in the production of 
Nicoliana plants that have decreased levels of nornicotine and 
its metabolite, the nitrosamine N'-nitrosonomicotine, Within 
the leaf and stem tissues. When harvested, the leaf and stem 
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tissues of these plants can be utiliZed to produce tobacco 
products having reduced levels of nomicotine and this 
tobacco-speci?c nitrosamine, and thus reduced carcinogenic 
potential for individuals consuming these products or 
exposed to secondary smoke derived from these products. 
Also provided are transgenic Nicoliana plants having a 
nicotine to nomicotine conversion rate of less than about 2%, 
Where the plants comprise a heterologous nucleic acid con 
struct comprising a promoter capable of functioning in a plant 
cell operably linked to a nucleic acid sequence having a ?rst 
nucleotide sequence comprising a fragment of betWeen about 
100 nucleotides and about 400 nucleotides of a Nicoliana 
nicotine demethylase polynucleotide and a second nucleotide 
sequence capable of forming a double- stranded RNA With the 
?rst nucleotide sequence, Where the transgenic Nicoliana 
plants are transgenic converter lines of Nicoliana. In some 
embodiments, the Nicoliana nicotine demethylase poly 
nucleotide is a tobacco nicotine demethylase polynucleotide. 
The present invention also provides a recombinant nucleic 
acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
having a ?rst nucleotide sequence comprising a fragment of 
betWeen about 100 nucleotides and about 400 nucleotides of 
a tobacco nicotine demethylase polynucleotide and a second 
nucleotide sequence capable of forming a double-stranded 
RNA With the ?rst nucleotide sequence. 
Also provided are methods of reducing the conversion of 
nicotine to nornicotine in a Nicoliana plant comprising trans 
forming a Nicoliana plant With a recombinant nucleic acid 
construct comprising a promoter capable of functioning in a 
plant cell operably linked to a nucleic acid sequence having a 
?rst nucleotide sequence comprising a fragment of betWeen 
about 100 nucleotides and about 400 nucleotides of a Nicoti 
ana nicotine demethylase polynucleotide and a second nucle 
otide sequence capable of forming a double-stranded RNA 
With the ?rst nucleotide sequence; and regenerating a trans 
genic Nicoliana plant. In some embodiments, the Nicoliana 
nicotine demethylase polynucleotide is a tobacco nicotine 
demethylase polynucleotide. 
The present invention also provides seed obtained from the 
transgenic Nicoliana plant having a nicotine to nornicotine 
conversion rate of less than about 2%, Where the seed com 
prises a heterologous nucleic acid construct comprising a 
promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence having a ?rst nucleotide 
sequence comprising a fragment of betWeen about 100 nucle 
otides and about 400 nucleotides of a Nicoliana nicotine 
demethylase polynucleotide and a second nucleotide 
sequence capable of forming a double- stranded RNA With the 
?rst nucleotide sequence, Where the transgenic Nicoliana 
plants are transgenic converter lines of Nicoliana. In some 
embodiments, the Nicoliana nicotine demethylase poly 
nucleotide is a tobacco nicotine demethylase polynucleotide. 
The present invention also provides transgenic plant cells 
comprising a nucleic acid molecule having a promoter func 
tional in a plant cell and a nucleic acid sequence encoding a 
nicotine demethylase having an isoleucine residue at position 
274 and a tryptophan residue at position 330. 
The present invention also provides methods of screening 
for a nicotine demethylase sequence comprising: obtaining a 
nucleic acid sequence that has greater than about 90% 
sequence identity With SEQ ID N015 and identifying a codon 
sequence encoding for a tryptophan residue at position 330 of 
the encoded polypeptide. 
Further provided are methods for screening for a nicotine 
demethylase having an isoleucine at position 274 or a tryp 
tophan at position 330 comprising obtaining a nucleic acid 
US 7,884,263 B2 
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sequence that has greater than about 90% sequence identity 
With SEQ ID N015 and identifying a ?rst codon sequence 
encoding for an isoleucine residue at position 274 or a second 
codon sequence encoding a tryptophan residue at position 
330 of the encoded polypeptide. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs the structures of nicotine, nornicotine, and 
N'-nitrosonornicotine (NNN). 
FIG. 2 shoWs Northern blot analysis of converter and non 
converter RNAs using 7D_A06 as a hybridization probe. 
Lanes 1 and 2 shoW RNAs isolated from sodium bicarbonate 
treated leaves of genotypes DH 98-325-5 (nonconverter) and 
DH 98-325-6 (converter), respectively. Lanes 3 and 4 shoW 
RNAs isolated from ethephon-treated leaves of genotypes 
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), 
respectively. Estimated size of the hybridizing band is indi 
cated in kilobases (kb). 
FIG. 3A-3G shoWs a nucleotide sequence alignment of 
members of the 3D_Cl2 gene family. Asterisks denote posi 
tions Where sequence identity is conserved among all 
sequences compared. Positions Where differences are found 
are indicated With dashes and the corresponding residues are 
shaded grey. The nucleotide sequences present in the align 
ment include 3D_Cl2 (SEQ ID N011), 3D_Cl2-l0 (SEQ ID 
N013); 3D_Cl2-7 (SEQ ID N015); 7D_A06 (SEQ ID N017); 
3D_Cl2-l5 (SEQ ID N019); and 131A_A02 (SEQ ID 
N01ll). The 3D_Cl2-l5 and l3lA_A02 entries are partial 
length cDNA sequences. The 99 bp region of 3D_Cl2 that 
Was used to make the RNAi-based construct is underlined. 
FIG. 4 shoWs an alignment of predicted amino acid 
sequences for full-length members of the 3D_Cl2 family of 
P450 genes. The amino acid sequences present in the align 
ment include 3D_Cl2 (SEQ ID N012), 3D_Cl2-l0 (SEQ ID 
N014); 3D_Cl2-7 (SEQ ID N016); and 7D_A06 (SEQ ID 
N01 8). Asterisks denote positions conserved among all four 
sequences. Residues that differ among the members are 
shaded in grey. 
FIG. 5 shoWs a Northern blot analysis of transgenic plants 
possessing the 3D_Cl2/RNAi construct. (A) Hybridization 
of the 3D_Cl2-7 probe to RNAs isolated from ethephon 
treated, cured leaves of transgenic plants displaying loW nor 
nicotine phenotypes (3D_Cl2/RNAi-l, 3, and 4) and high 
nomicotine phenotypes (3D_Cl2/RNAi-6, 7, and vector 
only control plant 11). Estimated size of hybridizing band is 
indicated in kilobases (kb). (B) Ethidium bromide staining of 
the portion of the gel used in (A) that contains the 28S ribo 
somal RNA to shoW the relative equivalence of RNA loading 
among the lanes. 
FIG. 6 shoWs a Northern blot analysis of transgenic plants 
possessing sense-orientation constructs of members of the 
3D_Cl2 gene family. (A) Hybridization of the 3D_Cl2-7 
probe to RNAs isolated from nontreated leaves of indepen 
dent transgenic lines expressing 3D_Cl2-7, 3D_Cl2, and 
7D_A06 constructs and a vector-only control (control 8). 
Estimated size of hybridizing band is indicated in kilobases 
(kb). (B) Ethidium bromide staining of the portion of the gel 
used in (A) that contains the 28S ribosomal RNA to shoW the 
relative equivalence of RNA loading among the lanes. 
FIG. 7 shoWs a genomic sequence of a fragment of the 
3D_Cl2-l0 gene (see SEQ ID N01 23) possessing an intron. 
Intron sequences are indicated in bold, italicized type. Exon 
sequences are shoWn in plain type. The sequences corre 
sponding to the PCR primers used to amplify the fragment 
from the tobacco genomic DNA are underlined. 
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FIG. 8A shoWs a diagram of the RNAi constructs used to 
silence expression of members of the 3D_CDl2 gene family; 
and FIG. 8B shoWs a diagram of the RNAi binary expression 
vector, pKYLX7 l /RNAi. 
DETAILED DESCRIPTION OF THE INVENTION 
Background and De?nitions 
Before describing the present invention in detail, it is to be 
understood that many modi?cations and other embodiments 
of the inventions set forth herein Will come to mind to one 
skilled in the art to Which this invention pertains having the 
bene?t of the teachings presented in the foregoing descrip 
tions and the associated draWings. Therefore, it is to be under 
stood that the invention is not to be limited to the speci?c 
embodiments disclosed and that modi?cations and other 
embodiments are intended to be included Within the scope of 
the appended claims. Rather, these embodiments are pro 
vided so that this disclosure Will satisfy applicable legal 
requirements. 
Although speci?c terms are employed herein, they are used 
in a generic and descriptive sense only and not for purposes of 
limitation. Like numbers refer to like elements throughout. 
Further, the article “a” and “an” are used herein to refer to one 
or more than one (i.e., to at least one) of the grammatical 
object of the article. By Way of example, “an element” means 
one or more element. Throughout the speci?cation the Word 
“comprising,” or variations such as “comprises” or “compris 
ing,” Will be understood to imply the inclusion of a stated 
element, integer or step, or group of elements, integers or 
steps, but not the exclusion of any other element, integer or 
step, or group of elements, integers or steps. 
The present invention is draWn to compositions and meth 
ods for inhibiting the expression or function of cytochrome 
P450 polypeptides that are involved in the metabolic conver 
sion of nicotine to nornicotine in a plant, particularly plants of 
the Nicoliana genus, including tobacco plants of the various 
commercial varieties. As used herein, the terms “inhibit,” 
“inhibition,” and “inhibiting” are de?ned as any method 
knoWn in the art or described herein that decreases the expres 
sion or function of a gene product of interest (i.e., the target 
gene product). “Inhibition” can be in the context of a com 
parison betWeen tWo plants, for example, a genetically altered 
plant versus a Wild-type plant. Alternatively, inhibition of 
expression or function of a target gene product can be in the 
context of a comparison betWeen plant cells, organelles, 
organs, tissues, or plant parts Within the same plant or 
betWeen different plants, and includes comparisons betWeen 
developmental or temporal stages Within the same plant or 
plant part or betWeen plants or plant parts. “Inhibition” 
includes any relative decrement of function or production of 
a gene product of interest, up to and including complete 
elimination of function or production of that gene product. 
The term “inhibition” encompasses any method or composi 
tion that doWn-regulates translation and/or transcription of 
the target gene product or functional activity of the target gene 
product. 
The term “inhibitory sequence” encompasses any poly 
nucleotide or polypeptide sequence capable of inhibiting the 
expression or function of a cytochrome P450 polypeptide 
involved in the metabolic conversion of nicotine to nomico 
tine in a plant, such as full-length polynucleotide or polypep 
tide sequences, truncated polynucleotide or polypeptide 
sequences, fragments of polynucleotide or polypeptide 
sequences, variants of polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense 
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oriented nucleotide sequences, the complement of a sense- or 
antisense-oriented nucleotide sequence, inverted regions of 
nucleotide sequences, hairpins of nucleotide sequences, 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. The 
term “polynucleotide sequence” includes sequences of RNA, 
DNA, chemically modi?ed nucleic acids, nucleic acid ana 
logs, combinations thereof, and the like. 
Inhibitory sequences are designated herein by the name of 
the target gene product. Thus, a “cytochrome P450 inhibitory 
sequence” refers to an inhibitory sequence that is capable of 
inhibiting the expression of a cytochrome P450 polypeptide 
that is involved in the metabolic conversion of nicotine to 
nomicotine in a plant, for example, at the level of transcrip 
tion and/or translation, or Which is capable of inhibiting the 
function of such a cytochrome P450 polypeptide. When the 
phrase “capable of inhibiting” is used in the context of a 
polynucleotide inhibitory sequence, it is intended to mean 
that the inhibitory sequence itself exerts the inhibitory effect; 
or, Where the inhibitory sequence encodes an inhibitory 
nucleotide molecule (for example, hairpin RNA, miRNA, or 
double-stranded RNA polynucleotides), or encodes an inhibi 
tory polypeptide (i.e., a polypeptide that inhibits expression 
or function of the target gene product), folloWing its transcrip 
tion (for example, in the case of an inhibitory sequence encod 
ing a hairpin RNA, miRNA, or double-stranded RNA poly 
nucleotide) or its transcription and translation (in the case of 
an inhibitory sequence encoding an inhibitory polypeptide), 
the transcribed or translated product, respectively, exerts the 
inhibitory effect on the target gene product (i.e., inhibits 
expression or function of the target gene product). 
By “host cell” is meant a cell that comprises a heterologous 
nucleic acid sequence of the invention. Though the nucleic 
acid sequences of the invention, and fragments and variants 
thereof, can be introduced into any cell of interest, of particu 
lar interest are plant cells, more particularly cells of a Nicoti 
ana plant species, for example, the tobacco plant species and 
varieties described herein beloW. 
The use of the term “polynucleotide” is not intended to 
limit the present invention to polynucleotides comprising 
DNA. Those of ordinary skill in the art Will recogniZe that 
polynucleotides can comprise ribonucleotides and combina 
tions of ribonucleotides and deoxyribonucleotides. Such 
deoxyribonucleotides and ribonucleotides include both natu 
rally occurring molecules and synthetic analogues. The poly 
nucleotides of the invention also encompass all forms of 
sequences including, but not limited to, single-stranded 
forms, double-stranded forms, hairpins, stem-and-loop struc 
tures, and the like. 
The term “variant” as used herein is intended to mean a 
substantially similar sequence, and the term “native” poly 
nucleotide or polypeptide is intended to mean a naturally 
occurring nucleotide sequence or amino acid sequence, 
respectively. By “fragment” is intended a portion of a poly 
nucleotide or a portion of an amino acid sequence and hence 
protein encoded thereby. 
As used herein, the term “plant part” includes plant cells, 
plant protoplasts, plant cell tissue cultures from Which a 
Whole plant can be regenerated, plant calli, plant clumps, and 
plant cells that are intact in plants or parts of plants such as 
embryos, pollen, anthers, ovules, seeds, leaves, ?owers, 
stems, branches, fruit, roots, root tips, and the like. Progeny, 
variants, and mutants of regenerated plants are also included 
Within the scope of the invention, provided that these com 
prise the introduced nucleic acid sequences of the invention. 
By “phenotypic change” is intended a measurable change 
in one or more cell functions. For example, plants having a 
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genetic modi?cation at the genomic locus encoding a cyto 
chrome P450 polypeptide of the invention can shoW reduced 
or eliminated expression or activity of that cytochrome P450 
polypeptide. 
The term “introducing” is intended to mean presenting to 
the plant the polynucleotide or polypeptide in such a manner 
that the sequence gains access to the interior of a cell of the 
plant. 
The term “operably linked” is intended to mean a func 
tional linkage betWeen tWo or more elements. For example, 
an operable linkage betWeen a polynucleotide of interest and 
a regulatory sequence (i.e., a promoter) is a functional link 
that alloWs for expression of the polynucleotide of interest. 
Operably linked elements may be contiguous or non-contigu 
ous. When used to refer to the joining of tWo protein coding 
regions, by operably linked is intended that the coding regions 
are in the same reading frame. 
The term “heterologous” according to the present inven 
tion When used in reference to a sequence is intended to mean 
a sequence that originates from a foreign species, or, if from 
the same species, is substantially modi?ed from its native 
form in composition and/or genomic locus by deliberate 
human intervention. The term also is applicable to nucleic 
acid constructs, also referred to herein as “polynucleotide 
constructs” or “nucleotide constructs.” In this manner, a “het 
erologous” nucleic acid construct is intended to mean a con 
struct that originates from a foreign species, or, if from the 
same species, is substantially modi?ed from its native form in 
composition and/ or genomic locus by deliberate human inter 
vention. Heterologous nucleic acid constructs include, but are 
not limited to, recombinant nucleotide constructs that have 
been introduced into a plant or plant part thereof, for example, 
via transformation methods or subsequent breeding of a 
transgenic plant With another plant of interest. 
For example, a promoter operably linked to a heterologous 
polynucleotide is from a species different from the species 
from Which the polynucleotide Was derived, or, if from the 
same/analogous species, one or both are substantially modi 
?ed from their original form and/or genomic locus, or the 
promoter is not the native promoter for the operably linked 
polynucleotide. Furthermore, as used herein a chimeric gene 
comprises a coding sequence operably linked to a transcrip 
tion initiation region that is heterologous to the coding 
sequence. 
The term “expression” as used herein refers to the biosyn 
thesis of a gene product, including the transcription and/or 
translation of said gene product. For example, for the pur 
poses of the present invention, an expression cassette, as 
described elseWhere herein, capable of expressing a poly 
nucleotide that inhibits the expression of at least one cyto 
chrome P450 polypeptide of the invention is an expression 
cassette capable of producing an RNA molecule that inhibits 
the transcription and/or translation of at least one cytochrome 
P450 polypeptide. The “expression” or “production” of a 
protein or polypeptide from a DNA molecule refers to the 
transcription and translation of the coding sequence to pro 
duce the protein or polypeptide, While the “expression” or 
“production” of a protein or polypeptide from an RNA mol 
ecule refers to the translation of the RNA coding sequence to 
produce the protein or polypeptide. 
Cytochrome 450 Polynucleotides and Polypeptides, andVari 
ants and Fragments Thereof 
Compositions of the present invention include isolated 
cytochrome P450 polynucleotides and polypeptides that are 
involved in the metabolic conversion of nicotine to nomico 
tine in plants, including commercial varieties of tobacco 
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plants. In particular, compositions of the invention include 
isolated polypeptides comprising the amino acid sequences 
as shoWn in SEQ ID NOS12, 4, 6, 8, 10, and 12, and isolated 
polynucleotides comprising the nucleotide sequences as 
shoWn in SEQ ID NOS11, 3, 5, 7, 9, and 11. The polynucle 
otides of the invention ?nd use in inhibiting expression of 
these cytochrome P450 polypeptides or variants thereof that 
are involved in the metabolic conversion of nicotine to nor 
nicotine in plants, particularly tobacco plants. 
In this manner, the invention further provides expression 
cassettes comprising all or a portion of the polynucleotide 
sequence set forth in SEQ ID N011, 3, 5, 7, 9, or 11, a 
complement or fragment thereof, or a sequence having sub 
stantial sequence identity to SEQ ID N011, 3, 5, 7, 9, or 11, or 
a complement or fragment thereof, operably linked to a pro 
moter that is functional in a plant cell for use in expressing an 
inhibitory RNA transcript that interferes With expression (i.e., 
transcription and/or translation) of cytochrome P450 
polypeptides described herein. In some embodiments, the 
expression cassettes comprise the nucleotide sequence as 
shoWn in SEQ ID N0113, 14, 15, or 16, a complement or 
fragment thereof, or a sequence having substantial sequence 
identity to SEQ ID N0113, 14, 15, or 16, or a complement or 
fragment thereof. Introduction of these expression cassettes 
into a Nicoliana plant of interest, particularly a tobacco plant 
of varieties commonly knoWn as ?ue or bright varieties, Bur 
ley varieties, dark varieties, and oriental/Turkish varieties, 
results in the production of tobacco plants having reduced 
amounts of nomicotine and the nitrosamine, N'-nitrosonorni 
cotine (NNN). Leaf and stem material from these transgenic 
plants can be used to produce a variety of tobacco products 
having reduced levels of nornicotine, and a concomitant 
reduction in this carcinogenic nitrosamine metabolite. 
The cytochrome P450 polynucleotides and encoded 
polypeptides of the present invention represent a novel cyto 
chrome P450 gene family, designated the 3D_C12 cyto 
chrome 450 gene family, that is neWly identi?ed as having a 
role in the metabolic conversion of nicotine to nomicotine in 
tobacco plants. Suppression of the expression of their 
encoded gene products in transgenic tobacco plants results in 
a signi?cant reduction in the accumulation of nomicotine in 
the leaves of these transgenic plants. While not being bound 
by theory, the metabolic role of these polypeptides may be a 
direct one, i.e., directly catalyZing the N-demethylation reac 
tion, or an indirect one, i.e., in the form of production of a 
product that leads to the up-regulation of the nicotine dem 
ethylase activity of the leaf. Regardless of the mechanism, 
any means by Which expression and/or function of the 
polypeptides encoded by members of this cytochrome P450 
gene family are targeted for inhibition Within a Nicoliana 
plant Will be effective in reducing nomicotine levels, and 
levels of its carcinogenic metabolite, NNN, Within leaves and 
stems of these plants. 
The cytochrome P450 genes of the invention Were isolated 
from tobacco lines of a Burley variety. The ?rst of these 
cytochrome P450 genes, designated 3D_C12, encodes an 
mRNA transcript corresponding to nucleotides (nt) 1-1551 of 
the cDNA sequence set forth in SEQ ID N011, Which codes 
for the full-length 517-residue polypeptide set forth in SEQ 
ID N012. The second member of this novel cytochrome P450 
family, designated 3D_C12-10, encodes an mRNA transcript 
corresponding to nt 1-1551 of the cDNA sequence set forth in 
SEQ ID N013, Which codes for the full-length 517-residue 
polypeptide set forth in SEQ ID N014. The third of these 
cytochrome P450 genes, designated 3D_C12-7, encodes an 
mRNA transcript corresponding to nt 1-1551 of the cDNA 
sequence set forth in SEQ ID N015, Which codes for the 
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full-length 517 residue polypeptide set forth in SEQ ID N016. 
The fourth member of the novel cytochrome P450 family, 
designated 7D_A06, encodes an mRNA transcript corre 
sponding to nt 1-1554 of the cDNA sequence set forth in SEQ 
ID N017, Which codes for the full-length 518-residue 
polypeptide set forth in SEQ ID N018. 
TWo partial-length P450 gene sequences sharing high 
sequence identity to the full-length members of the 3D_C12 
cytochrome P450 gene family Were also isolated from these 
Burley tobacco lines. The ?rst of these, designated 3D_C12 
15, encodes an mRNA transcript corresponding to the cDNA 
sequence set forth in SEQ ID N019, Which encodes the par 
tial-length polypeptide set forth in SEQ ID N0110. The sec 
ond partial-length P450 gene sequence, designated 
131A_A02, encodes an mRNA transcript corresponding to 
the cDNA sequence set forth in SEQ ID N0111, Which 
encodes the partial-length polypeptide set forth in SEQ ID 
N01 12. 
In one aspect, the cytochrome P450 genes of the present 
invention are involved in the conversion of nicotine to norni 
cotine in a plant. In one aspect, the cytochrome P450 genes of 
the present invention have nicotine demethylase activity. 
An alignment of the members of the 3D_C12 cytochrome 
P450 gene family is shoWn in FIG. 3A-3G. The predicted 
amino acid sequences for the four full-length clones are 
aligned in FIG. 4. These sequences share high sequence iden 
tity With each other (at least 90% at both the nucleotide and 
amino acid level (see Tables 2 and 3, Example 4 herein 
beloW). 
The invention encompasses isolated or substantially puri 
?ed polynucleotide or protein compositions. An “isolated” or 
“puri?ed” polynucleotide or protein, or biologically active 
portion thereof, is substantially or essentially free from com 
ponents that normally accompany or interact With the poly 
nucleotide or protein as found in its naturally occurring envi 
ronment. Thus, an isolated or puri?ed polynucleotide or 
protein is substantially free of other cellular material, or cul 
ture medium When produced by recombinant techniques, or 
substantially free of chemical precursors or other chemicals 
When chemically synthesiZed. 0ptimally, an “isolated” poly 
nucleotide is free of sequences (optimally protein encoding 
sequences) that naturally ?ank the polynucleotide (i.e., 
sequences located at the 5' and 3' ends of the polynucleotide) 
in the genomic DNA of the organism from Which the poly 
nucleotide is derived. For example, in various embodiments, 
the isolated polynucleotide can contain less than about 5 kb, 
4 kb, 3 kb, 2 kb, lkb, 0.5 kb, or 0.1 kb ofnucleotide sequence 
that naturally ?ank the polynucleotide in genomic DNA of the 
cell from Which the polynucleotide is derived. A protein that 
is substantially free of cellular material includes preparations 
of protein having less than about 30%, 20%, 10%, 5%, or 1% 
(by dry Weight) of contaminating protein. When the protein of 
the invention or biologically active portion thereof is recom 
binantly produced, optimally culture medium represents less 
than about 30%, 20%, 10%, 5%, or 1% (by dry Weight) of 
chemical precursors or non-protein-of-interest chemicals. 
Fragments of the disclosed cytochrome P450 polynucle 
otides and polypeptides encoded thereby are also encom 
passed by the present invention. Fragments of a polynucle 
otide may encode protein fragments that retain the biological 
activity of the native protein and hence are involved in the 
metabolic conversion of nicotine to nomicotine in a plant. 
Alternatively, fragments of a polynucleotide that are useful as 
hybridization probes or PCR primers using methods 
described beloW generally do not encode fragment proteins 
retaining biological activity. Furthermore, fragments of the 
disclosed nucleotide sequences include those that can be 















































